Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Acquires China Rights to Kidney Disease Treatment in $121 Million Pact

publication date: Jun 10, 2019

China's Everest Medicines signed a $121 million pact for Greater China rights to Nefecon, the lead drug of Sweden's Calliditas Therapeutics. Nefecon is a novel oral formulation of the corticosteroid budesonide aimed at treating chronic autoimmune kidney disease IgA Nephropathy (IgAN). In Sweden, Calliditas has completed a successful Phase IIb trial of Nefecon as a treatment for inflammatory kidney disease in patients at risk of progressing to renal failure. Everest will pay $15 million upfront and the rest in milestones. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here